Research Questions Prescription Drug's Claims in Women

by Rajashri on September 19, 2008 at 5:51 PM
 Research Questions Prescription Drug's Claims in Women

New research has found that Lipitor does not reduce the risk of cardiovascular problems in women leading experts to question the benefits of the drug in women.

Lipitor has been the top-selling drug in the world and has accounted for over 12 billion dollars in annual sales.


It has been prescribed to both men and women to lower cholesterol and reduce the risk of heart attack and stroke in patients with common risk factors for heart disease.

Now, the latest study was unable to find high quality clinical evidence documenting reduced heart attack risk for women in a primary prevention context.

Also, the study by Theodore Eisenberg of Cornell Law School and Martin T. Wells of Cornell University, also claims that the advertisements for the drug doesn't include label information relevant to women.

For the study, the researchers assembled studies for a meta analysis of drugs' effects on cardiovascular risk, considering all relevant studies reporting risks for both men and women.

No study including women with a mixture of risk factors for heart attacks gave any heed to the prescription of Lipitor or other statins to protect against cardiovascular problems.

Pfizer's claims of clinical proof that Lipitor reduces risk of heart attack in patients with multiple risk factors for heart disease does not appear to be scientifically supported for large segments of the female population.

Also, Lipitor's advertising repeatedly fails to report that clinical trials were statistically significant for men but not for women. Thus, unqualified advertising claims of protection against heart attacks may be misleading.

Pfizer's advertising also does not disclose critical portions of the Lipitor FDA-approved label, which acknowledges the absence of evidence with respect to women.

"Our findings indicate that each year, reasonably healthy women spend billions of dollars on drugs in the hope of preventing heart attacks but that scientific evidence supporting their hope does not exist," concluded the authors.

The study is appearing in the Journal of Empirical Legal Studies.

Source: ANI
Font : A-A+



Recommended Readings

Latest Drug News

Prolonging Market Exclusivity of Brand-name Insulin
Examining FDA and patent records, researchers found that insulin manufacturers prolong market exclusivity for brand-name products.
FDA Boosts Orphan Drug Designations for Myelofibrosis Treatments
The rise in FDA ODD awards indicates a collective endeavor to create new myelofibrosis medications devoid of mechanisms inducing anemia.
Anti-Rheumatic Drugs May Help Prevent Thyroid Disease
The most significant decrease in autoimmune thyroid disease risk was observed in rheumatoid arthritis patients receiving immunomodulatory drugs or 'biological DMARDs'.
Apotransferrin's Potential in Early Stroke Therapy Revealed
Human apotransferrin injected to mice models suffering from intracerebral hemorrhage was found to mitigate the serious effects of stroke.
Anti-cancer Drug Navitoclax Help Treat Lower Back Pain
The reduction of these senescent osteoclasts, possibly through the utilization of current medications, could present a novel approach in managing lower back pain.
View All
This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close

Research Questions Prescription Drug's Claims in Women Personalised Printable Document (PDF)

Please complete this form and we'll send you a personalised information that is requested

You may use this for your own reference or forward it to your friends.

Please use the information prudently. If you are not a medical doctor please remember to consult your healthcare provider as this information is not a substitute for professional advice.

Name *

Email Address *

Country *

Areas of Interests